Cargando…

Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy

PURPOSE: Until 2018, National Cancer Comprehensive Network guidelines recommended androgen deprivation therapy (ADT) for all men with intermediate-risk prostate cancer who had undergone radiation therapy. Intermediate risk was stratified as favorable and unfavorable in 2018, and ADT recommendation w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agrawal, Vishesh, Ma, Xiaoyue, Hu, Jim C., Barbieri, Christopher E., Nagar, Himanshu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Scientific Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260097/ https://www.ncbi.nlm.nih.gov/pubmed/35814856 http://dx.doi.org/10.1016/j.adro.2022.100904

Ejemplares similares

Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US
por: Agrawal, Vishesh, et al.
Publicado: (2020)

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer
por: Gadia, Rafael, et al.
Publicado: (2016)

Postmastectomy Radiation Therapy Bolus Associated Complications in Patients Who Underwent 2-stage Breast Reconstruction
por: de Sousa, Cecília Félix Penido Mendes, et al.
Publicado: (2022)

A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer
por: Hamid, Muhammad, et al.
Publicado: (2021)

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
por: Johnson, Matthew E., et al.
Publicado: (2012)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
por: Shah, Neil J, et al.
Publicado: (2022)

Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy
por: Sebastian, Nikhil, et al.
Publicado: (2023)

Patients’ Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
por: De, Brian, et al.
Publicado: (2022)

Analysis of Radiation Facility Volume and Survival in Men With Lymph Node–Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy
por: Patel, Sagar A., et al.
Publicado: (2020)

Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003
por: Laughlin, Brady S., et al.
Publicado: (2022)

The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation
por: Ludwig, Michelle S, et al.
Publicado: (2015)

Urinary quality of life outcomes in men who were treated with image-guided intensity-modulated radiation therapy for prostate cancer
por: Salami, Simpa S., et al.
Publicado: (2016)

Androgen deprivation and SARS-CoV-2 in men with prostate cancer
por: Koskinen, M., et al.
Publicado: (2020)

Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy
por: Valeriani, Maurizio, et al.
Publicado: (2013)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
por: Morrison, Belinda F, et al.
Publicado: (2011)

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer
por: Gagliano-Jucá, Thiago, et al.
Publicado: (2018)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2021)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021)

Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study
por: Gresswell, Steven, et al.
Publicado: (2016)

Diminished health and social outcomes among men who have sex with men who use drugs in Zimbabwe
por: Mapingure, Munyaradzi, et al.
Publicado: (2023)

Analysis of SARS-COV-2 in Bronchial Samples in Asymptomatic or Unsuspected Patients Who Underwent Scheduled Bronchoscopy After Negative Screening
por: Marques, Tânia Sales, et al.
Publicado: (2022)

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2023)

Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy
por: Kalina, Jennifer L., et al.
Publicado: (2017)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
por: Nguyen, Paul L., et al.
Publicado: (2015)

Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
por: Jayadevappa, Ravishankar, et al.
Publicado: (2019)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
por: Fradin, James, et al.
Publicado: (2023)

Two Elderly Men with Myasthenia Gravis during Androgen Deprivation Therapy for Prostate Cancer
por: Kanazawa, Kazo, et al.
Publicado: (2023)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

How do we define “castration” in men on androgen deprivation therapy?
por: Itty, Sarin, et al.
Publicado: (2020)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer
por: Boyd, Kathleen A, et al.
Publicado: (2015)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Efficacy and Prognostic Factors of Androgen Deprivation Therapy Combined with Radiation Therapy for Prostate Cancer
por: Zeng, Siping, et al.
Publicado: (2021)

Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis
por: Leal, Frederico, et al.
Publicado: (2015)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
por: Neubecker, Katherine, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_t1jck5fv5qo9vu0fu806j9o2e5